ALNYALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $3.7B
- 65% YoY
- Operating margin
- 13.5%
- 272% YoY
- EBITDA
- $556M
- 557% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.9×
- −$1.1B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear167% of net incomeCash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $844M | $1.0B | $1.8B | $2.2B | $3.7B | 65% |
| Operating income | −$709M | −$785M | −$282M | −$177M | $502M | 384% |
| Net income | −$853M | −$1.1B | −$440M | −$278M | $314M | 213% |
| Operating cash flow | −$642M | −$541M | $104M | −$8M | $524M | 6405% |
| Capex | $76M | $72M | $62M | $34M | $59M | 71% |
| Stock-based comp | $166M | $231M | $222M | $272M | $348M | 28% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 13
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $15M | $77M | 306 | 125 |
| FY2024 | $11M | $30M | 181 | 93 |
| FY2023 | $9M | $11M | 147 | 94 |
| FY2022 | $5M | $19M | 183 | 90 |
| FY2021 | $10M | $18M | 130 | 100 |